single agents in the metastatic disease setting based on several randomized phase III trials. 18 , 19 Cisplatin is a standard backbone of combination chemotherapy regimens, and cisplatin-based chemotherapy regimens (eg, cisplatin/paclitaxel/bevacizumab
Search Results
Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, Kathleen R. Cho, Christina Chu, David Cohn, Marta Ann Crispens, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Ernest Han, Warner K. Huh, John R. Lurain III, David Mutch, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Nelson Teng, Todd Tillmanns, Fidel A. Valea, Catheryn M. Yashar, Nicole R. McMillian, and Jillian L. Scavone
Presented by: Alan P. Venook and Christopher G. Willett
“The introduction of FOLFOX and bevacizumab in the early 2000s raised our hopes that progress would be rapid and definitive. Although patients with advanced disease now live longer than in the past—many for ≥3 years—progress has largely stalled
Dung T. Le and Elizabeth M. Jaffee
antigen-specific T cells and other agents to block T-cell inhibitory signals. Commercial grade agents are available or will become available to test in combinations. Examples include: 1) bevacizumab; 2) celecoxib; 3) GCS-100; 4) GC-1008; 5
Thomas Kaley and Louis B. Nabors
-refractory meningiomas represents an unmet clinical need. There are no FDA-approved therapies. The NCCN Guidelines suggest sunitinib, interferon alfa, or bevacizumab plus everolimus as category B recommendations.” RANO Review “This review was based on 43 publications on
Eric T. Wong and Steven Brem
: 347 – 356 . 2. Folkman J . Tumor angiogenesis: therapeutic implications . N Engl J Med 1971 ; 285 : 1182 – 1186 . 3. Willett CG Boucher Y di Tomaso E . Direct evidence that the VEGF-specific antibody bevacizumab has
Presented by: Midhun Malla, Katrina S. Pedersen, and Aparna R. Parikh
metastatic CRC space, the combination of trifluridine/tipiracil + bevacizumab has emerged as a potential new standard of care based on findings from the SUNLIGHT study. This open-label, randomized phase III trial enrolled patients with refractory metastatic
William T. McGivney
Recent decisions about the optimal frequency and population age for screening mammography and the appropriate uses of bevacizumab and sipuleucel-t have raised questions, if not concerns, about both the decision-making processes and the level of
Al B. Benson, Michael I. D’Angelica, Daniel E. Abbott, Daniel A. Anaya, Robert Anders, Chandrakanth Are, Melinda Bachini, Mitesh Borad, Daniel Brown, Adam Burgoyne, Prabhleen Chahal, Daniel T. Chang, Jordan Cloyd, Anne M. Covey, Evan S. Glazer, Lipika Goyal, William G. Hawkins, Renuka Iyer, Rojymon Jacob, R. Kate Kelley, Robin Kim, Matthew Levine, Manisha Palta, James O. Park, Steven Raman, Sanjay Reddy, Vaibhav Sahai, Tracey Schefter, Gagandeep Singh, Stacey Stein, Jean-Nicolas Vauthey, Alan P. Venook, Adam Yopp, Nicole R. McMillian, Cindy Hochstetler, and Susan D. Darlow
against lenvatinib alone for the frontline treatment of unresectable or metastatic HCC ( ClinicalTrials.gov identifier: NCT03713593). Atezolizumab and Bevacizumab Bevacizumab, a VEGF inhibitor, has modest clinical activity as a single agent or in
Saby George, Roberto Pili, Michael A. Carducci, and Jenny J. Kim
). Furthermore, although the use of single-agent interferon has decreased significantly since the introduction of targeted therapy, it remains in the frontline setting in combination with bevacizumab as a result of 2 large phase III trials. 1 Lastly, improved
Emil Lou, Donna D'Souza, and Andrew C. Nelson
carcinoembryonic antigen (CEA) biomarker while on combination chemotherapy (FOLFIRI with bevacizumab), bevacizumab was discontinued in favor of initiating an EGFR inhibitor (panitumumab) while continuing the FOLFIRI backbone. This alteration to her treatment
